Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04550325
Recruitment Status : Recruiting
First Posted : September 16, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Kamada, Ltd.

Brief Summary:
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia

Condition or disease Intervention/treatment Phase
Covid19 Pneumonia, Viral Biological: Kamada Anti-SARS-CoV-2 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: A Phase 1/2 Open Label, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients with Pneumonia
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia
Actual Study Start Date : August 5, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: Immune gamma globulin (IgG)
Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
Biological: Kamada Anti-SARS-CoV-2
Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods




Primary Outcome Measures :
  1. Adverse events, serious adverse events, and deaths [ Time Frame: 14 days ]
    Record adverse events, serious adverse events, and deaths

  2. Adverse events, serious adverse events, and deaths [ Time Frame: 28 days ]
    Record adverse events, serious adverse events, and deaths


Secondary Outcome Measures :
  1. AUC0-7 of Anti SARS CoV-2 antibodies [ Time Frame: 7 days ]
    Measurement of the area under the curve of anti SARS CoV-2 immunoglobulin

  2. Neutralization activity [ Time Frame: 7 days ]
    Evaluate virus neutralization activity of patient's plasma


Other Outcome Measures:
  1. Duration of Hospitalization [ Time Frame: 84 days ]
    Time patient spent in hospital

  2. Clinical status on the 6 point ordinate scale [ Time Frame: 84 days ]
    Score on the 6 point ordinate scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR)
  3. Hospitalized for COVID-19 pneumonia
  4. Dosing should be within 10 days of symptom start
  5. Able and willing to sign informed consent form

Exclusion Criteria:

  1. History of hypersensitivity to plasma products and/or severe Immunoglobulin A deficiency (< 7 mg/dL)
  2. Requirement of high flow oxygen devices, or non-invasive ventilation or mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) at screening
  3. Cardiovascular instability
  4. History of thrombo-embolic events
  5. Acute renal failure or creatinine >2 mg/dL or estimated estimated glomerular filtration rate (eGFR) <30 mL/min
  6. History of lung transplantation
  7. Major surgery (abdominal and chest) within the last 4 weeks
  8. Severe chronic background disease, per investigator's judgement for example, Cirrhosis grade C, Dialysis, cardiac insufficiency (NYHA III), pulmonary disease (FEV1<50 percent of predicted) etc.
  9. Pregnancy or lactation
  10. Treatment with plasma units or immunoglobulin preparations within the last 4 weeks
  11. Participation in another pharmaceutical interventional clinical study within 4 weeks from screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04550325


Contacts
Layout table for location contacts
Contact: Sharon Castro, MSc +972 8 9406472 Sharonc@kamada.com

Locations
Layout table for location information
Israel
Wolfson Medical Center Recruiting
Holon, Israel, 5822012
Hadassah Medical Center Recruiting
Jerusalem, Israel, 91120
Sheba Medical Center Hospital- Tel Hashomer Recruiting
Ramat Gan, Israel, 52621
Kaplan Medical Center Recruiting
Reẖovot, Israel, 7661041
Sponsors and Collaborators
Kamada, Ltd.
Layout table for additonal information
Responsible Party: Kamada, Ltd.
ClinicalTrials.gov Identifier: NCT04550325    
Other Study ID Numbers: Kamada Anti-SARS-CoV-2-001
First Posted: September 16, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases